Pendium

Step 1 of 9

Dexcom owns the medical CGM conversation, but the wellness opening is still being claimed by competitors.

Your clinical visibility is excellent, yet there is a significant opportunity to compound your lead by capturing the broader metabolic health and biohacking audience.

Dexcom's baseline score
84/100
Excellent

Dexcom has world-class AI visibility in the medical diabetes category, with near-universal recommendation for accuracy. However, newer wellness-focused software layers are currently getting more credit from AI for the metabolic health use case.

What we see
  • Dexcom dominates 'best CGM for Type 1' queries across all four AI platforms due to a decade of clinical leadership.
  • Abbott is often suggested alongside Dexcom as a lower-cost alternative, particularly in Gemini and AI Overviews which prioritize price-comparison content.
  • Wellness-focused brands like Levels and Nutrisense frequently 'steal' mentions for metabolic health prompts, even though they use Dexcom hardware.
  • Claude is the most likely to provide a balanced comparison of Dexcom vs. Medtronic, citing specific integration capabilities with insulin pumps.
Business goals Dexcom is likely trying to hit
  • Defend market share against Abbott's FreeStyle Libre 3
  • Expand into the metabolic health and wellness market for non-diabetics
  • Drive adoption of the Dexcom G7 among Type 2 diabetes patients
  • Increase direct-to-consumer subscriptions through insurance and out-of-pocket channels